{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:07:30Z","timestamp":1761894450316},"reference-count":51,"publisher":"Elsevier BV","issue":"6-7","license":[{"start":{"date-parts":[[2007,5,1]],"date-time":"2007-05-01T00:00:00Z","timestamp":1177977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2007,5]]},"DOI":"10.1016\/j.euroneuro.2006.11.007","type":"journal-article","created":{"date-parts":[[2007,1,17]],"date-time":"2007-01-17T07:21:36Z","timestamp":1169018496000},"page":"456-463","source":"Crossref","is-referenced-by-count":13,"title":["A 6-month prospective, observational, naturalistic, uncontrolled study to evaluate the effectiveness and tolerability of oral ziprasidone in patients with schizophrenia"],"prefix":"10.1016","volume":"17","author":[{"given":"C.","family":"Arango","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"G\u00f3mez-Beneyto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Brenlla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Gast\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Sarramea-Crespo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Chamorro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X.","family":"Masramon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"D\u00edez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2006.11.007_bib1","series-title":"Presented at the 156th annual meeting of the American Psychiatric Association; May 17\u201322, 2003; San Francisco, California","article-title":"Ziprasidone vs risperidone in schizophrenia: 52\u00a0weeks' comparative data","author":"Addington","year":"2003"},{"key":"10.1016\/j.euroneuro.2006.11.007_bib2","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.4088\/JCP.v65n1207","article-title":"Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial","volume":"65","author":"Addington","year":"2004","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2006.11.007_bib3","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1176\/ajp.156.11.1686","article-title":"Antipsychotic-induced weight gain: a comprehensive research synthesis","volume":"156","author":"Allison","year":"1999","journal-title":"Am. J. Psychiatry"},{"year":"2004","series-title":"Practice Guideline for the Treatment of Patients With Schizophrenia","author":"American Psychiatric Association","key":"10.1016\/j.euroneuro.2006.11.007_bib4"},{"key":"10.1016\/j.euroneuro.2006.11.007_bib5","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.eurpsy.2003.10.004","article-title":"The deficit syndrome in schizophrenia: implications for the treatment of negative symptoms","volume":"19","author":"Arango","year":"2004","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.euroneuro.2006.11.007_bib6","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/00004850-200209000-00001","article-title":"A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160\u00a0mg\/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study","volume":"17","author":"Arato","year":"2002","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2006.11.007_bib7","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1176\/appi.ajp.163.3.488","article-title":"Negative signs and symptoms secondary to antipsychotics: a double-blind, randomized trial of a single dose of placebo, haloperidol, and risperidone in healthy volunteers","volume":"163","author":"Artaloytia","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2006.11.007_bib8","unstructured":"Bagnall A.-M., Lewis R.A., Leitner M.L. (2004). Ziprasidone for schizophrenia and severe mental illness (Cochrane Review). The Cochrane Library, Issue 1, Oxford."},{"key":"10.1016\/j.euroneuro.2006.11.007_bib9","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/S0006-3223(99)00088-8","article-title":"Deficit psychopathology and a paradigm shift in schizophrenia research","volume":"46","author":"Carpenter","year":"1999","journal-title":"Biol. Psychiatry"},{"issue":"Suppl. 19","key":"10.1016\/j.euroneuro.2006.11.007_bib10","first-page":"40","article-title":"Tolerability of ziprasidone: an expanding perspective","volume":"64","author":"Daniel","year":"2003","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2006.11.007_bib11","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0893-133X(98)00090-6","article-title":"Ziprasidone 80\u00a0mg\/day and 160\u00a0mg\/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group","volume":"20","author":"Daniel","year":"1999","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2006.11.007_bib12","series-title":"Outcome measurement in psychiatry","article-title":"Outcome measurement from research to clinical practice","author":"Dickey","year":"2002"},{"issue":"47","key":"10.1016\/j.euroneuro.2006.11.007_bib34","doi-asserted-by":"crossref","first-page":"10831","DOI":"10.1523\/JNEUROSCI.2999-05.2005","article-title":"Involvement of 5-HT1A receptors in prefrontal cortex in the modulation of dopaminergic activity: role in atypical antipsychotic action","volume":"25","author":"D\u0131az-Mataix","year":"2005","journal-title":"J. Neurosci."},{"key":"10.1016\/j.euroneuro.2006.11.007_bib13","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/00004850-200015030-00001","article-title":"A comparison of the effects of quetiapine (\u2018seroquel\u2019) and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment. PRIZE Study Group","volume":"15","author":"Emsley","year":"2000","journal-title":"Int. Clin. Psychopharmacol."},{"year":"1998","series-title":"Fundamentals of Clinical Trials","author":"Friedman","key":"10.1016\/j.euroneuro.2006.11.007_bib14"},{"key":"10.1016\/j.euroneuro.2006.11.007_bib15","first-page":"261","article-title":"El Cuestionario de Actitud hacia la Medicaci\u00f3n (Drug Attitude Inventory: DAI-30) en poblaci\u00f3n espa\u00f1ola","volume":"64","author":"Garcia","year":"2001","journal-title":"Arch. Psiquiatr."},{"key":"10.1016\/j.euroneuro.2006.11.007_bib16","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/00004850-200507000-00002","article-title":"Pharmacological treatment and other predictors of treatment outcomes in previously untreated patients with schizophrenia: results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study","volume":"20","author":"Gasquet","year":"2005","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2006.11.007_bib17","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1097\/00004714-199808000-00009","article-title":"An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder","volume":"18","author":"Goff","year":"1998","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2006.11.007_bib18","doi-asserted-by":"crossref","first-page":"335","DOI":"10.4088\/JCP.v61n0503","article-title":"The safety of olanzapine compared with other antipsychotic drugs: results of an observational prospective study in patients with schizophrenia (EFESO Study). Pharmacoepidemiologic Study of Olanzapine in Schizophrenia","volume":"61","author":"Gomez","year":"2000","journal-title":"J. Clin. Psychiatry."},{"key":"10.1016\/j.euroneuro.2006.11.007_bib19","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0140-6736(02)07283-5","article-title":"An overview of clinical research: the lay of the land","volume":"359","author":"Grimes","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.euroneuro.2006.11.007_bib20","unstructured":"Guy W., 1976. ECDEU Assessment Manual for Psychopharmacology -Revised (DHEW Publ No ADM 76\u2013338). Rockville, MD, U.S. Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs, pp. 218\u2013222."},{"key":"10.1016\/j.euroneuro.2006.11.007_bib21","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/j.1600-0447.2004.00450.x","article-title":"Effectiveness of antipsychotic treatment for schizophrenia: 6-month results of the Pan-European Schizophrenia Outpatient Health Outcomes (SOHO) study","volume":"111","author":"Haro","year":"2005","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.euroneuro.2006.11.007_bib22","doi-asserted-by":"crossref","first-page":"516","DOI":"10.4088\/JCP.v63n0609","article-title":"A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia","volume":"63","author":"Hirsch","year":"2002","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2006.11.007_bib23","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1097\/00004714-200012000-00019","article-title":"Selection bias in clinical trials with antipsychotics","volume":"20","author":"Hofer","year":"2000","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2006.11.007_bib24","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1017\/S0033291700050182","article-title":"A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity","volume":"13","author":"Hogan","year":"1983","journal-title":"Psychol. Med."},{"key":"10.1016\/j.euroneuro.2006.11.007_bib25","unstructured":"International Federation of Pharmaceutical Manufacturers and Associations (IFPMA). Medical Dictionary for Regulatory Affaire, MedDRA V 8.0, 1 March 2005."},{"year":"2000","series-title":"Management Issues in Schizophrenia","author":"Kane","key":"10.1016\/j.euroneuro.2006.11.007_bib26"},{"issue":"Suppl. 12","key":"10.1016\/j.euroneuro.2006.11.007_bib27","first-page":"1","article-title":"The expert consensus guideline series: optimizing pharmacologic treatment of psychotic disorders","volume":"64","author":"Kane","year":"2003","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2006.11.007_bib28","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2006.11.007_bib29","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/0165-1781(88)90038-8","article-title":"Reliability and validity of the positive and negative syndrome scale for schizophrenics","volume":"23","author":"Kay","year":"1988","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.euroneuro.2006.11.007_bib30","doi-asserted-by":"crossref","first-page":"S178","DOI":"10.1097\/00005650-198903001-00015","article-title":"Effect sizes for interpreting changes in health status","volume":"27","author":"Kazis","year":"1989","journal-title":"Med. Care"},{"key":"10.1016\/j.euroneuro.2006.11.007_bib31","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s002130050755","article-title":"Ziprasidone 40 and 120\u00a0mg\/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial","volume":"140","author":"Keck","year":"1998","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.euroneuro.2006.11.007_bib32","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/hup.723","article-title":"Efficacy and tolerability of quetiapine in patients with schizophrenia who switched from haloperidol, olanzapine or risperidone","volume":"20","author":"Larmo","year":"2005","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2006.11.007_bib33","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"22","author":"Lieberman","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.euroneuro.2006.11.007_bib35","series-title":"The Expert Consensus Guideline Series: Treatment of Schizophrenia 1999","first-page":"1","volume":"vol. 60","year":"1999"},{"key":"10.1016\/j.euroneuro.2006.11.007_bib36","series-title":"Presented at the 156th Annual Meeting of the American Psychiatric Association; May 17\u201322, San Francisco, California","article-title":"Optimal dosing of oral ziprasidone: analysis of clinical trial data","author":"Murray","year":"2003"},{"key":"10.1016\/j.euroneuro.2006.11.007_bib37","first-page":"0001a","article-title":"Expanding the frontier of treatment research","volume":"2","author":"Norquist","year":"1999","journal-title":"Prev. Treat."},{"key":"10.1016\/j.euroneuro.2006.11.007_bib38","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1080\/10673220127892","article-title":"Short-term inpatient pharmacotherapy of schizophrenia","volume":"9","author":"Osser","year":"2001","journal-title":"Harv. Rev. Psychiatry"},{"key":"10.1016\/j.euroneuro.2006.11.007_bib39","first-page":"171","article-title":"Validaci\u00f3n de la escala de los s\u00edndromes positivo y negativo (PANSS) en una muestra de esquizofr\u00e9nicos espa\u00f1oles","volume":"22","author":"Peralta","year":"1994","journal-title":"Actas Luso Esp. Neurol. Psiquiatr."},{"key":"10.1016\/j.euroneuro.2006.11.007_bib40","series-title":"Comprehensive care of schizophrenia","article-title":"Pharmacological treatment of schizophrenia","author":"Siegfried","year":"2001"},{"key":"10.1016\/j.euroneuro.2006.11.007_bib41","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1176\/appi.ajp.161.10.1837","article-title":"Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder","volume":"161","author":"Simpson","year":"2004","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2006.11.007_bib42","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1176\/appi.ajp.162.8.1535","article-title":"Six-month, blinded, multicenter continuation study of ziprasidone versus olanzapine in schizophrenia","volume":"162","author":"Simpson","year":"2005","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2006.11.007_bib43","doi-asserted-by":"crossref","first-page":"6","DOI":"10.4088\/JCP.v62n0102","article-title":"Does evidence from clinical trials in psychopharmacology apply in clinical practice?","volume":"62","author":"Stahl","year":"2001","journal-title":"J. Clin. Psychiatry"},{"issue":"Suppl. 19","key":"10.1016\/j.euroneuro.2006.11.007_bib44","first-page":"6","article-title":"The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice","volume":"64","author":"Stahl","year":"2003","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2006.11.007_bib45","first-page":"137","article-title":"Novel antipsychotics: issues and controversies. Typicality of atypical antipsychotics","volume":"25","author":"Stip","year":"2000","journal-title":"J. Psychiatry Neurosci."},{"key":"10.1016\/j.euroneuro.2006.11.007_bib46","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1177\/070674370204700607","article-title":"The 2 \u201cEs\u201d of research: efficacy and effectiveness trials","volume":"47","author":"Streiner","year":"2002","journal-title":"Can. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2006.11.007_bib47","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nrd1956","article-title":"Clinical trials for antipsychotic drugs: design conventions, dilemmas and innovations","volume":"5","author":"Stroup","year":"2006","journal-title":"Nat. Rev., Drug Discov."},{"issue":"Suppl. 3","key":"10.1016\/j.euroneuro.2006.11.007_bib48","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1097\/00004850-199803003-00004","article-title":"The role of negative symptoms and cognitive dysfunction in schizophrenia outcome","volume":"13","author":"Tamminga","year":"1998","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2006.11.007_bib49","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1136\/bmj.317.7167.1181","article-title":"Content and quality of 2000 controlled trials in schizophrenia over 50\u00a0years","volume":"317","author":"Thornley","year":"1998","journal-title":"BMJ"},{"key":"10.1016\/j.euroneuro.2006.11.007_bib50","doi-asserted-by":"crossref","first-page":"420","DOI":"10.4088\/JCP.v63n0508","article-title":"Clinical predictors of response to clozapine treatment in ambulatory patients with schizophrenia","volume":"63","author":"Umbricht","year":"2002","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2006.11.007_bib51","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1176\/ajp.156.1.5","article-title":"Treatment research at the crossroads: the scientific interface of clinical trials and effectiveness research","volume":"156","author":"Wells","year":"1999","journal-title":"Am. J. Psychiatry"}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X06002574?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X06002574?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T07:52:32Z","timestamp":1683705152000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X06002574"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,5]]},"references-count":51,"journal-issue":{"issue":"6-7","published-print":{"date-parts":[[2007,5]]}},"alternative-id":["S0924977X06002574"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2006.11.007","relation":{},"ISSN":["0924-977X"],"issn-type":[{"type":"print","value":"0924-977X"}],"subject":[],"published":{"date-parts":[[2007,5]]}}}